CompletedNCT00186017
Olanzapine added to usual treatment for acute mania
About this title
Read the official source — NCT00186017Medication studyAges 18–70United StatesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
- Listed locations
- StanfordSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Stanford University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00186017
- Official title
Show the full official title
Double-Blind Placebo-Controlled Olanzapine Add-on Therapy in the Treatment of Acute Syndromal and Subsyndromal Exacerbations in Bipolar Disorders
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Stanford
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Stanford University, a university.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine/Zyprexa.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.
